2.66 USD
-0.02 (-0.75%)
2.6762 USD
+0.02 (+0.61%)
HITI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. The financial health of HITI is average, but there are quite some concerns on its profitability. HITI has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
HITI had negative earnings in the past year.
In the past year HITI had a positive cash flow from operations.
HITI had negative earnings in each of the past 5 years.
HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
HITI has a Return On Assets of -3.76%. This is in the better half of the industry: HITI outperforms 73.82% of its industry peers.
HITI's Return On Equity of -6.93% is fine compared to the rest of the industry. HITI outperforms 76.44% of its industry peers.
The Return On Invested Capital of HITI (5.06%) is better than 82.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.76% | ||
| ROE | -6.93% | ||
| ROIC | 5.06% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HITI has a better Operating Margin (2.30%) than 78.01% of its industry peers.
HITI has a Gross Margin of 25.83%. This is comparable to the rest of the industry: HITI outperforms 54.97% of its industry peers.
HITI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.3% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
HITI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for HITI has been increased compared to 1 year ago.
HITI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HITI has been reduced compared to a year ago.
2.2 Solvency
HITI has an Altman-Z score of 3.07. This indicates that HITI is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.07, HITI is doing good in the industry, outperforming 64.92% of the companies in the same industry.
The Debt to FCF ratio of HITI is 4.08, which is a neutral value as it means it would take HITI, 4.08 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 4.08, HITI belongs to the best of the industry, outperforming 84.82% of the companies in the same industry.
A Debt/Equity ratio of 0.43 indicates that HITI is not too dependend on debt financing.
The Debt to Equity ratio of HITI (0.43) is worse than 61.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 4.08 | ||
| Altman-Z | 3.07 |
ROIC/WACC0.61
WACC8.36%
2.3 Liquidity
A Current Ratio of 1.85 indicates that HITI should not have too much problems paying its short term obligations.
HITI has a worse Current ratio (1.85) than 64.40% of its industry peers.
A Quick Ratio of 1.29 indicates that HITI should not have too much problems paying its short term obligations.
HITI has a worse Quick ratio (1.29) than 69.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
The earnings per share for HITI have decreased strongly by -328.07% in the last year.
Looking at the last year, HITI shows a quite strong growth in Revenue. The Revenue has grown by 11.18% in the last year.
HITI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 75.59% yearly.
EPS 1Y (TTM)-328.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%13.67%
3.2 Future
Based on estimates for the next years, HITI will show a very strong growth in Earnings Per Share. The EPS will grow by 74.44% on average per year.
The Revenue is expected to grow by 15.74% on average over the next years. This is quite good.
EPS Next Y3.81%
EPS Next 2Y103.67%
EPS Next 3Y96.71%
EPS Next 5Y74.44%
Revenue Next Year13.63%
Revenue Next 2Y21.39%
Revenue Next 3Y17.79%
Revenue Next 5Y15.74%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
HITI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 27.24 indicates a quite expensive valuation of HITI.
Based on the Price/Forward Earnings ratio, HITI is valued a bit cheaper than the industry average as 73.82% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of HITI to the average of the S&P500 Index (23.88), we can say HITI is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.24 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HITI indicates a rather cheap valuation: HITI is cheaper than 90.05% of the companies listed in the same industry.
85.86% of the companies in the same industry are more expensive than HITI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.33 | ||
| EV/EBITDA | 9.39 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HITI does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as HITI's earnings are expected to grow with 96.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.67%
EPS Next 3Y96.71%
5. Dividend
5.1 Amount
No dividends for HITI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.66
-0.02 (-0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners13.66%
Inst Owner Change0%
Ins Owners8.85%
Ins Owner ChangeN/A
Market Cap232.09M
Revenue(TTM)568.25M
Net Income(TTM)-9.80M
Analysts80
Price Target5.33 (100.38%)
Short Float %4.69%
Short Ratio6.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)194.66%
Min EPS beat(2)-8%
Max EPS beat(2)397.33%
EPS beat(4)1
Avg EPS beat(4)15.55%
Min EPS beat(4)-315.76%
Max EPS beat(4)397.33%
EPS beat(8)5
Avg EPS beat(8)75.15%
EPS beat(12)9
Avg EPS beat(12)61.94%
EPS beat(16)12
Avg EPS beat(16)45.88%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)3
Avg Revenue beat(4)0.59%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.6%
Revenue beat(8)5
Avg Revenue beat(8)0.02%
Revenue beat(12)9
Avg Revenue beat(12)1.49%
Revenue beat(16)13
Avg Revenue beat(16)7.4%
PT rev (1m)1.52%
PT rev (3m)2.15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)14.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.24 | ||
| P/S | 0.57 | ||
| P/FCF | 16.33 | ||
| P/OCF | 11 | ||
| P/B | 2.28 | ||
| P/tB | 6.19 | ||
| EV/EBITDA | 9.39 |
EPS(TTM)-0.09
EYN/A
EPS(NY)0.1
Fwd EY3.67%
FCF(TTM)0.16
FCFY6.12%
OCF(TTM)0.24
OCFY9.09%
SpS4.7
BVpS1.17
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.76% | ||
| ROE | -6.93% | ||
| ROCE | 6.4% | ||
| ROIC | 5.06% | ||
| ROICexc | 7.36% | ||
| ROICexgc | 20.27% | ||
| OM | 2.3% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% | ||
| FCFM | 3.47% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score5
Asset Turnover2.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 4.08 | ||
| Debt/EBITDA | 1.67 | ||
| Cap/Depr | 41.17% | ||
| Cap/Sales | 1.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 80.65% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | 3.07 |
F-Score5
WACC8.36%
ROIC/WACC0.61
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-328.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y3.81%
EPS Next 2Y103.67%
EPS Next 3Y96.71%
EPS Next 5Y74.44%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%13.67%
Revenue Next Year13.63%
Revenue Next 2Y21.39%
Revenue Next 3Y17.79%
Revenue Next 5Y15.74%
EBIT growth 1Y2.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year424.94%
EBIT Next 3Y133.23%
EBIT Next 5Y81.43%
FCF growth 1Y38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.53%
OCF growth 3YN/A
OCF growth 5YN/A
HIGH TIDE INC / HITI FAQ
What is the fundamental rating for HITI stock?
ChartMill assigns a fundamental rating of 4 / 10 to HITI.
What is the valuation status for HITI stock?
ChartMill assigns a valuation rating of 4 / 10 to HIGH TIDE INC (HITI). This can be considered as Fairly Valued.
Can you provide the profitability details for HIGH TIDE INC?
HIGH TIDE INC (HITI) has a profitability rating of 3 / 10.
Can you provide the expected EPS growth for HITI stock?
The Earnings per Share (EPS) of HIGH TIDE INC (HITI) is expected to grow by 3.81% in the next year.